Navigation Links
Study Unblinded: ZYTIGA® (abiraterone acetate) Plus Prednisone for Asymptomatic or Mildly Symptomatic Chemotherapy-Naive Patients with Metastatic Castration-Resistant Prostate Cancer
Date:3/8/2012

RARITAN, N.J., March 8, 2012 /PRNewswire/ -- Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA® (abiraterone acetate) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy.  

Study COU-AA-302 is an international, randomized, double-blind, placebo controlled study that included 1,088 patients who were randomized to receive ZYTIGA 1,000 milligrams (mg) administered once daily plus prednisone 5 mg administered twice daily or placebo plus prednisone 5 mg administered twice daily. The co-primary endpoints of the study are radiographic progression-free survival and overall survival.

The Independent Data Monitoring Committee (IDMC) unanimously recommended unblinding the study based on a planned interim analysis in which differences in radiographic progression-free survival, overall survival, and secondary endpoints were observed that constitute evidence of clinical benefit as well as continued evidence of favorable safety in patients receiving abiraterone acetate plus prednisone as compared to those receiving placebo plus prednisone.  Based on these results, the IDMC also recommended that patients in the placebo arm be offered treatment with ZYTIGA.

These results will be presented at an upcoming medical meeting and will also be submitted for publication in a peer-reviewed journal.

"The COU-AA-302 study has been a key priority for us as we expand our understanding of the utility of ZYTIGA in metastatic prostate cancer," said William N. Hait, MD, PhD, Global Head, Janssen R&D.  "We're delighted that these data will soon be added to the growing body of literature about this important medication."

ZYTIGA has not been approved for use in men with metastatic CRPC who have not yet received chemotherapy.  The company plans to s
'/>"/>

SOURCE Janssen Research & Development, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Minn. , Sept. 2, 2015  MGC Diagnostics ... scheduled a conference call to discuss its financial results ... 31, 2015. The call will be at 4:30 p.m. ... report financial results for the third quarter of fiscal ... 2015. Participants can dial (877) 317-6789 ...
(Date:9/2/2015)... -- Delcath Systems, Inc. (NASDAQ: DCTH ), a ... with an emphasis on the treatment of primary and ... in the upcoming 17 th Annual Rodman & ... the St. Regis Hotel in New York City.  ... Chief Executive Officer, will present a corporate overview and ...
(Date:9/2/2015)... -- Kastle Therapeutics (Kastle), a biopharmaceutical company focused on ... high unmet medical needs, announced today that it ... positions. Sean McAuliffe has ... Global Marketing Director for Baxalta. Nick Smith ... and Analytics; Nick was previously Director, Forecasting and ...
Breaking Medicine Technology:MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 2Delcath To Present At The 17th Annual Rodman & Renshaw Conference 3Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
... COPAN announced this week that it has received the ... for collection and transfer of biological samples. The Japanese ... a growing number of patents held by COPAN across ... collection and transfer of biological samples, including the Australian ...
... Sept. 13 Tomorrow night, "Dan Rather Reports" will ...  These are not just lifestyle drugs like Viagra or ... like Aricept, used for the treatment of Alzheimer,s and ... is netting billions of dollars for criminals while, potentially ...
Cached Medicine Technology:COPAN Secures Japanese Patent for its Flocked Swab Innovation 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 2Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 3Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 4Are the Prescription Drugs You Are Taking Real, or Counterfeit? HDNet's Dan Rather Reports Investigates 5
(Date:9/2/2015)... ... ... On September 9, 2015, over 27,000 people from all over the world ... date for the state of Utah. , “We are thrilled with the overwhelming response ... doTERRA CEO. “One of the most exciting elements of our convention is the opportunity ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in ... awareness and education, and helping fund more research remains our top priority,” commented ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is National Prostate ... that affects more than 233,000 men each year in the United States. , Prostate ... common non-skin cancer in America, affecting 1 in 7 men. One new case occurs ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... cells continue to flow to newborn in minutes after birth, ... women may want to consider asking their doctors to hold ... after the baby is born, a new study suggests. , ... the blood flow from mom to baby. While not necessarily ...
... experts say , WEDNESDAY, May 26 (HealthDay News) -- Malignant ... tens of thousands of genetic mutations which, together, contribute to ... lung tumor from a heavy smoker revealed 50,000 mutations, according ... Nature . , "People in the field have always known ...
... Complete Genomics Inc., a third-generation human genome sequencing company, ... of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), ... sequence and compare a patient,s primary lung tumor and ... to compare the patient,s genome before and after it ...
... treatment of anaplastic thyroid carcinoma has dramatically increased survival in ... say physicians at Mayo Clinic. Their findings will be presented ... Clinical Oncology , to be held June 4-8 in Chicago. ... to aggressively treat metastasis even when this rare cancer seems ...
... ... first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest Region. ... ... the first Community of Respect™ Medical Center in the Anti-Defamation League’s (ADL’s) Southwest ...
... ... up to $100,000 per-violation penalties , ... Alexandria, VA (Vocus) May 26, 2010 -- More than ten major ... Network (CEN) offered by the National Association of Chain Drug Stores (NACDS) and RollStream. ...
Cached Medicine News:Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 2Health News:Waiting to Clamp the Umbilical Cord May Be Better for Babies 3Health News:Single Lung Tumor Contains 50,000 Mutations 2Health News:Genentech uses Complete Genomics' human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature 2Health News:New treatment approach to rare cancer results in prolonged survival 2Health News:Houston Northwest Medical Center Becomes First Hospital in the Southwest Region Designated a Community of Respect™ Partner 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 2Health News:Retailers and Manufacturers Quickly Adopt Online Network to Address CPSIA Compliance 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: